A practical reference on obesity research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-09. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
== Metabolic diseases == Early studies in the area reported that a liver-derived protein, alpha2-HS Glycoprotein, also known as Fetuin-A, can inhibit insulin tyrosine kinase activation and might play a role in the pathogenesis of metabolic disorders. Results suggest that hepatokine production could remodel metabolic homeostasis. This is exemplified by a number of studies revealing that hepatokines play a pivotal role in metabolism and contribute to the development of obesity, insulin resistance, T2D, NAFL, and NASH (109, 149). So far, ~20 hepatokines have been described to be involved in the regulation of energy and nutrient metabolism by acting directly on the liver or on distal target tissues. Hepatokines can be remodelled depending on the environment, for example, exercise-training can remodel hepatokine secretion. Little work in human hepatokines has been performed, however, using precision-cut liver slicing of human livers with and without MASH over 2000 hepatokines were described with potential roles in either promoting or protecting cardiometabolic disease pathogenesis. Hepatokines are now considered potential targets for the treatment of cardiometabolic disorders.
The enzyme characterised from Saccharopolyspora erythraea converts erythromycin D into erythromycin C by introduction of a hydroxy group at the C-12 position of the macrocycle. It uses reduced nicotinamide adenine dinucleotide phosphate (NADPH) and oxygen as cofactors. Erythromycin C is subsequently converted to the antibiotic, erythromycin A, by the enzyme erythromycin 3''-O-methyltransferase.
The two-fold purpose of the double-lumen technology was: (i) the aesthetic benefits of silicone gel (contained in the inner lumen) that is enclosed within the outer lumen, which is filled with saline solution; and (ii) a breast prosthesis whose volume is post-operatively adjustable. In surgical practise, the double-lumen prosthetic breast is used primarily in reconstructive surgery of the breasts.
Both copies of the affected gene must carry the same mutation (homozygous condition) for a person to be affected by an autosomal recessive disorder. An affected person usually has unaffected parents, each of whom carries one mutated gene and one normal gene (heterozygous condition) and is referred to as a genetic carrier; they may not have any symptoms. When both parents have the sickle cell trait, any given child has a 25% chance of sickle cell disease; a 25% chance of no sickle cell alleles, and a 50% chance of the heterozygous condition (see diagram). There are several different haplotypes of the sickle cell gene mutation, indicating that it may have arisen spontaneously in different geographic areas. The variants are known as Cameroon, Senegal, Benin, Bantu, and Saudi-Asian. These are clinically important because some are associated with higher HbF levels, e.g., Senegal and Saudi-Asian variants, and tend to have milder disease. The gene defect is a single nucleotide mutation of the β-globin gene, which results in the amino acid glutamic acid being substituted by valine at position 6 of the β-globin chain. Haemoglobin S with this mutation is referred to as HbS, as opposed to the normal adult HbA. Under conditions of normal oxygen concentration, this causes no apparent effects on the structure of haemoglobin or its ability to transport oxygen around the body. However, the deoxy form of HbS has an exposed hydrophobic patch, which causes HbS molecules to form long, inflexible chains.
Hanning (1958), professor of English literature at Columbia University Neil Harris (1958), professor of art history at the University of Chicago Joachim Neugroschel (1958), prolific multilingual translator David Rothman (1958), professor of social medicine and president of the Institute on Medicine as a Profession John Clubbe (1959), professor of English at the University of Kentucky Benjamin Cohen (1959), political economist and authority on International political economy Richard Fremantle (1959), Anglo-American art historian, son of writer Anne Fremantle Robert Nozick (1959), libertarian philosopher known for his book Anarchy, State, and Utopia Isser Woloch (1959), historian of the French Revolution Arnold A. Offner (1959), professor of history at Lafayette College and past president of Society for Historians of American Foreign Relations Riordan Roett (1959), political scientist and Latin American specialist at Johns Hopkins University Bruce M.
Sources: en.wikipedia.org
Viracor Eurofins Laboratories is a diagnostic laboratory specializing in infectious disease, immunology and allergy testing for immunocompromised and critical patients. Viracor Eurofins works with medical professionals, transplant teams, reference labs and bio-pharmaceutical companies. Viracor-IBT has CLIA clinical laboratory certification as both an Infectious Disease Laboratory and as an Allergy & Immunology Laboratory.
Theories suggest the claustrum may act to bind and integrate multisensory information, or else to encode sensory stimuli as salient or nonsalient (Mathur, 2014). One theory suggests the claustrum harmonizes and coordinates activity in various parts of the cortex, leading to the seamless integrated nature of subjective conscious experience (Crick and Koch, 2005; Stiefel et al., 2014). Disrupting claustral activity may lead to conscious experiences of disintegrated or unusually bound sensory information, perhaps including synesthesia. Such theories are in part corroborated by the fact that [salvia divinorum], which functions almost exclusively on the KOR system, can cause consciousness to be decoupled from external sensory input, leading to experiencing other environments and locations, perceiving other "beings" besides those actually in the room, and forgetting oneself and one's body in the experience. From this perspective, disrupting claustral activity might lead to conscious experiences of disintegrated or unusually bound sensory information, including synesthesia. However, even early formulations acknowledged that their assumptions are merely tentative and that "KORs are not exclusive to the claustrum; there is also a fairly high density of receptors located in the prefrontal cortex, hippocampus, nucleus accumbens and putamen", and that "disruptions to other brain regions could also explain the consciousness-altering effects [of salvinorin A]".
The origin of the modern smallpox vaccine has long been unclear, but horsepox was identified in the 2010s as the most likely ancestor. Edward Jenner had obtained his vaccine from a cow, so he named the virus vaccinia, after the Latin word for cow. Jenner believed that both cowpox and smallpox were viruses that originated in the horse and passed to the cow, and some doctors followed his reasoning by inoculating their patients directly with horsepox. The situation was further muddied when Louis Pasteur developed techniques for creating vaccines in the laboratory in the late 19th century. As medical researchers subjected viruses to serial passage, inadequate recordkeeping resulted in the creation of laboratory strains with unclear origins. By the late 19th century, it was unknown whether the vaccine originated from cowpox, horsepox, or an attenuated strain of smallpox. In 1939, Allan Watt Downie showed that the vaccinia virus was serologically distinct from the "spontaneous" cowpox virus. This work established vaccinia and cowpox as two separate viral species. The term vaccinia now refers only to the smallpox vaccine, while cowpox no longer has a Latin name. The development of whole genome sequencing in the 1990s made it possible to compare orthopoxvirus genomes and identify their relationships with each other. The horsepox virus was sequenced in 2006 and found to be most closely related to vaccinia. In a phylogenetic tree of the orthopoxviruses, horsepox forms a clade with vaccinia strains, and cowpox strains form a different clade.
When the Legion of Merit is awarded to members of the Armed Forces of the United States, it is awarded without reference to degree. However, the medal and ribbon of the fourth degree (Legionnaire) are used for members of the Armed Forces of the United States. The US Army and US Air Force do not authorize the "V" Device for the Legion of Merit. The U.S. Navy, the U.S. Marine Corps, and the United States Coast Guard do. The first U.S. Armed Forces recipient of the Legion of Merit medal was World War II combat veteran Lieutenant, junior grade, Ann Bernatitus, U.S.N., one of the "Angels of Bataan" and the only U.S. Navy nurse to escape from Bataan and Corregidor during the war. She was also the first person authorized to wear the "V" Device with the award. Her medal is now housed at the Smithsonian Institution.
Former faculty member Ernest Lyon was a United States ambassador to Liberia and the founder of the Maryland Industrial and Agricultural Institute for Colored Youths. Noted African American historian and pioneering scholar Dr. Benjamin A. Quarles served on its faculty for many decades. Physician-scientist Charles R. Drew, known for his work on blood transfusion, was Morgan College's first athletic director. African-American historian Rosalyn Terborg-Penn wrote on women's suffrage. Flora E. Strout, Morgan College teacher and principal, wrote the school's anthem. Notable faculty currently teaching at Morgan State University include bestselling author and filmmaker MK Asante, and scholar Raymond Winbush.
Sources: en.wikipedia.org
Esketamine has faster clearance and stronger dopamine inhibition than arketamine, contributing to its dissociative and psychotomimetic effects. In the form of racemic ketamine, esketamine was first synthesized in 1962 and introduced for medical use as an anesthetic in 1970. Enantiopure esketamine was introduced for medical use as an anesthetic in 1997 and as an antidepressant in 2019. It is used as an anesthetic in the European Union and as an antidepressant in the United States and Canada. Due to misuse liability as a dissociative, esketamine is a controlled substance.
Orthofluorofentanyl (o-fluorofentanyl, 2-fluorofentanyl) is an opioid analgesic that is an analog of fentanyl and has been sold online as a designer drug. While the structural isomer p-fluorofentanyl was one of the first illicit fentanyl analogues identified in 1981, Orthofluorofentanyl did not appear on the illicit market until August 2016.
It is not true that more people have died from the COVID-19 vaccine than from COVID-19 itself. Severe adverse reactions from the vaccine are rare, and an "exceedingly small" number of deaths have been caused by the vaccine. Meanwhile, the death toll from the disease itself is in the millions. Tuberculosis is not purely a disease of the lungs that has symptoms of coughing. It may instead infect a wide range of other organs in the body. Cancer cannot be treated by restricting food intake and so supposedly "starving" tumors. Rather, the health of people with cancer is best served by maintaining a healthy diet. The common cold and the common flu are caused by viruses, not exposure to cold temperatures. However, low temperatures may somewhat weaken the immune system, and someone already infected with a cold or influenza virus but showing no symptoms can become symptomatic after they are exposed to low temperatures. Viruses are more likely to spread during the winter for a variety of reasons such as dry air, less air circulation in homes, people spending more time indoors, and lower vitamin D levels in humans. Antibiotics will not cure a cold; they treat bacterial diseases and are ineffectual against viruses. However, they are sometimes prescribed to prevent or treat secondary infections. There is little to no evidence that any illnesses are curable through essential oils or aromatherapy, and fish oil has not been shown to cure dementia.
Mitochondrial myopathy Maternally inherited diabetes mellitus and deafness (MIDD) While diabetes mellitus and deafness can be found together for other reasons, at an early age this combination can be due to mitochondrial disease, as may occur in Kearns–Sayre syndrome and Pearson syndrome Leber's hereditary optic neuropathy (LHON) LHON is an eye disorder characterized by progressive loss of central vision due to degeneration of the optic nerves and retina (apparently affecting between 1 in 30,000 and 1 in 50,000 people); visual loss typically begins in young adulthood Leigh syndrome, subacute necrotizing encephalomyelopathy after normal development the disease usually begins late in the first year of life, although onset may occur in adulthood a rapid decline in function occurs and is marked by seizures, altered states of consciousness, dementia, ventilatory failure Neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP) progressive symptoms as described in the acronym dementia Myoneurogenic gastrointestinal encephalopathy (MNGIE) gastrointestinal pseudo-obstruction neuropathy MERRF syndrome progressive myoclonic epilepsy "Ragged Red Fibers" are clumps of diseased mitochondria that accumulate in the subsarcolemmal region of the muscle fiber and appear when muscle is stained with modified Gömöri trichrome stain short stature hearing loss lactic acidosis exercise intolerance MELAS syndrome, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes Mitochondrial DNA depletion syndrome Cancer: While the cancer cells prefer Warburg effect however efficient mitochondrial maintenance remains crucial for tumor resilience, redox regulation, and avoidance of cell death. Tumor cells exhibit metabolic heterogeneity, shifting between glycolysis and mitochondrial oxidative phosphorylation to meet energy demands and support growth, especially during metastasis. Key bioenergetic parameters such as oxygen flux, proton leakage, membrane potential, extracellular acidification rate (ECAR), and proton-motive force are examined as “sub-domains” that tumors may regulate to promote survival and evade apoptosis. Conditions such as Friedreich's ataxia can affect the mitochondria but are not associated with mitochondrial proteins.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.